Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 10Recruiting 7Terminated 5Active not recruiting 4Not yet recruiting 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma 5Lymphoma, B-Cell 3Leukemia 3Recurrence 2Lymphoma, Mantle-Cell 2Solid Tumors 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Indolent Non-Hodgkin's Lymphoma 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Disease 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1B-cell Malignancies 1

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × obinutuzumab × Clear all
NCT05896163 2026-05-06

MAPtivate-6

Pfizer

Phase 1/2 Terminated
40 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

University of Washington

Phase 2 Terminated
18 enrolled 14 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Terminated
29 enrolled 18 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01287741 2019-04-12

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Hoffmann-La Roche

Phase 3 Terminated
1,418 enrolled 20 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02420210 2018-06-06

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

University of Chicago

Phase 2 Terminated
2 enrolled 7 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡